Ibandronate sodium and Neoplasm malignant - a phase IV clinical study of FDA data

Summary:

Neoplasm malignant is reported as a side effect among people who take Ibandronate sodium (ibandronate sodium), especially for people who are female, 60+ old, have been taking the drug for 10+ years also take Zometa, and have Metastases to bone.

The phase IV clinical study analyzes which people have Neoplasm malignant when taking Ibandronate sodium. It is created by eHealthMe based on reports of 3,511 people who have side effects when taking Ibandronate sodium from the FDA, and is updated regularly.

What is Ibandronate sodium?

Ibandronate sodium has active ingredients of ibandronate sodium. It is often used in osteoporosis post-menopausal. eHealthMe is studying from 3,549 Ibandronate sodium users. Check the latest studies of Ibandronate sodium.

What is Neoplasm malignant?

Neoplasm malignant (cancer tumour) is found to be associated with 1,540 drugs and 1,261 conditions by eHealthMe. Check the latest studies of Neoplasm malignant.

eHealthMe: drug outcomes in the real world

eHealthMe runs one of the largest post-marketing drug safety studies in the world. We study millions of patients and 5,000 more each day. Our data-driven phase IV clinical trials have been referenced on 800+ peer-reviewed medical publications including The Lancet, Mayo Clinic Proceedings, and Nature. Tools to study our phase IV findings are available to the public, anonymous and free >>>.

On Aug, 30, 2026

3,511 people reported to have side effects when taking Ibandronate sodium.
Among them, 15 people (0.43%) have Neoplasm malignant.

Could Ibandronate sodium cause Neoplasm malignant?

Among these 15 people:

How long have people been on Ibandronate sodium when they have Neoplasm malignant? *

What is the gender of people who have Neoplasm malignant when taking Ibandronate sodium? *

female: 86.67 %
male: 13.33 %

What is the age of people who have Neoplasm malignant when taking Ibandronate sodium? *

What are other drugs people take besides Ibandronate sodium? *

What are other side effects people have besides Neoplasm malignant? *

Neoplasm Progression (growth of tumour): 6 people, 40.00%
Osteonecrosis Of Jaw (death of bone of jaw): 6 people, 40.00%
Pain: 5 people, 33.33%
Aphagia (inability or refusal to swallow): 4 people, 26.67%
Fall: 4 people, 26.67%
Metastases To Bone (cancer spreads to bone): 3 people, 20.00%
Diarrhea: 3 people, 20.00%
Pneumonia: 3 people, 20.00%
Urinary Tract Infection: 2 people, 13.33%
Hospitalisation: 2 people, 13.33%

What are the existing conditions these people have? *

Metastases To Bone (cancer spreads to bone): 3 people, 20.00%
Drowsiness: 2 people, 13.33%
Breast Cancer: 2 people, 13.33%
Pain: 2 people, 13.33%
Narcolepsy (brain's inability to regulate sleep-wake cycles normally): 2 people, 13.33%
Cataplexy (loss of muscle tone accompanied by full conscious awareness): 2 people, 13.33%
Transplant Rejection (a transplant material is not worked): 1 person, 6.67%
Bone Disorder: 1 person, 6.67%
Breast Cancer Metastatic: 1 person, 6.67%
Crohn's Disease (a condition that causes inflammation of the gastrointestinal tract): 1 person, 6.67%

* Approximation only. Some reports may have incomplete information.

Do you take Ibandronate sodium and have Neoplasm malignant?

- Check whether Neoplasm malignant is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Ibandronate sodium:

Ibandronate sodium (3,549 reports)

Browse all side effects of Ibandronate sodium:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Neoplasm malignant:

Neoplasm malignant (1,540 drugs)

Browse all the conditions that are associated with Neoplasm malignant:

Neoplasm malignant (1,261 conditions)

How the study uses the data?

The study uses data from the FDA. It is based on ibandronate sodium (the active ingredients of Ibandronate sodium) and Ibandronate sodium (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.